PTLA Portola Pharmaceuticals, Inc.

38.23
0  -1%
Previous Close 38.51
Open 38.41
Price To book 11.43
Market Cap 2.16B
Shares 56,557,000
Volume 984,209
Short Ratio 4.14
Av. Daily Volume 1,280,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
Phase 2 enrolment commenced May 2016. Continues to enroll as of November 2016.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
CRL August 17 2016
Andexanet alfa
Factor Xa inhibitor reversal agent

Latest News

  1. Why Portola Pharmaceuticals Stock Is Already Up an Eye-Popping 72% This Year
  2. Top Stocks That Are Already Crushing the Market in 2017
  3. Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets
  4. Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
  5. PORTOLA PHARMACEUTICALS INC Financials
  6. Is Portola Pharmaceuticals Balance Sheet Safe?
  7. ETFs with exposure to Portola Pharmaceuticals, Inc. : March 6, 2017
  8. Portola Pharmaceuticals, Inc. :PTLA-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  9. Top Biotech Stocks With FDA Decisions in 2017
  10. PORTOLA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
  11. Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
  12. Portola Pharmaceuticals posts 4Q loss
  13. Portola Pharmaceuticals posts 4Q loss
  14. Edited Transcript of PTLA earnings conference call or presentation 28-Feb-17 9:30pm GMT
  15. Why Is Portola Pharmaceuticals Stock Red Hot in 2017?
  16. PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
  17. Portola Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
  18. Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  19. Q4 2016 Portola Pharmaceuticals Inc Earnings Release - After Market Close
  20. Portola Pharma upgraded by Oppenheimer